Recent Updates
Recently added Catalysts
PODD Positive Sentiment

Insulet Reports Second Quarter 2026 Results

Key Takeaway: Insulet Corporation reported its financial results for Q2 2026, showcasing a revenue of $801.7 million, which represents a 23.5% increase compared to the previous year. This growth surpassed the company's guidance range of 20% to 22% in constant currency. The Omnipod product line contributed significantly, with total revenue of $795.9 million.

Market Sentiment Analysis

POSITIVE FACTORS

  • Revenue increased by 23.5%, exceeding company guidance.
  • Total Omnipod revenue reached $795.9 million.
  • Strong performance in constant currency rates.

Full Press Release Details

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader intubeless insulin pump technologywith its Omnipod®brand of products, today announced it will report financial results for the second quarter of 2026 on Wednesday, August 5, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time).
The link to the live call will be available on the Investor Relations section of the Company's website atinvestors.insulet.com, “Events and Presentations,” and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2109 for international callers; the passcode is 5904836.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit:Insulet.comoromnipod.com.
©2026 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved.

Investor Relations:Clare TrachtmanVice President, Investor Relationsir@insulet.comMedia:Cristal DowningChief Corporate Affairs Officerpr@insulet.com

Frequently Asked Questions

What were Insulet's Q2 2026 revenue figures?

Insulet reported a revenue of $801.7 million for Q2 2026.

How much did Omnipod revenue contribute in Q2 2026?

Total Omnipod revenue reached $795.9 million in Q2 2026.

Did Insulet meet its revenue guidance for Q2 2026?

Yes, Insulet exceeded its revenue guidance of 20% to 22% growth.

What was the percentage increase in revenue?

Insulet's revenue increased by 23.5% compared to the previous year.

Last updated: Aug 5, 2026